These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

129 related items for PubMed ID: 17479951

  • 1. Dysregulated energy expenditure in HIV-infected patients: a mechanistic review.
    Chang E, Sekhar R, Patel S, Balasubramanyam A.
    Clin Infect Dis; 2007 Jun 01; 44(11):1509-17. PubMed ID: 17479951
    [Abstract] [Full Text] [Related]

  • 2. Management trends. Resting energy expenditure in the HAART era.
    Shevitz AH.
    AIDS Read; 2000 Sep 01; 10(9):539-44; quiz 557-8. PubMed ID: 11019449
    [Abstract] [Full Text] [Related]

  • 3. Role of cytokines and testosterone in regulating lean body mass and resting energy expenditure in HIV-infected men.
    Roubenoff R, Grinspoon S, Skolnik PR, Tchetgen E, Abad L, Spiegelman D, Knox T, Gorbach S.
    Am J Physiol Endocrinol Metab; 2002 Jul 01; 283(1):E138-45. PubMed ID: 12067854
    [Abstract] [Full Text] [Related]

  • 4. Energy expenditure and protein metabolism in human immunodeficiency virus infection and cancer cachexia.
    Mulligan K, Bloch AS.
    Semin Oncol; 1998 Apr 01; 25(2 Suppl 6):82-91. PubMed ID: 9625389
    [Abstract] [Full Text] [Related]

  • 5. Energy expenditure and wasting in human immunodeficiency virus infection.
    Macallan DC, Noble C, Baldwin C, Jebb SA, Prentice AM, Coward WA, Sawyer MB, McManus TJ, Griffin GE.
    N Engl J Med; 1995 Jul 13; 333(2):83-8. PubMed ID: 7777033
    [Abstract] [Full Text] [Related]

  • 6. Increased resting energy expenditure, fat oxidation, and food intake in patients with highly active antiretroviral therapy-associated lipodystrophy.
    Sutinen J, Yki-Järvinen H.
    Am J Physiol Endocrinol Metab; 2007 Mar 13; 292(3):E687-92. PubMed ID: 17062843
    [Abstract] [Full Text] [Related]

  • 7. Nutrition in the era of highly active antiretroviral therapy.
    Shevitz AH, Knox TA.
    Clin Infect Dis; 2001 Jun 15; 32(12):1769-75. PubMed ID: 11360219
    [Abstract] [Full Text] [Related]

  • 8. Predictors of virological outcome and safety in primary HIV type 1-infected patients initiating quadruple antiretroviral therapy: QUEST GW PROB3005.
    Hoen B, Cooper DA, Lampe FC, Perrin L, Clumeck N, Phillips AN, Goh LE, Lindback S, Sereni D, Gazzard B, Montaner J, Stellbrink HJ, Lazzarin A, Ponscarme D, Staszewski S, Mathiesen L, Smith D, Finlayson R, Weber R, Wegmann L, Janossy G, Kinloch-de Loes S, QUEST Study Group.
    Clin Infect Dis; 2007 Aug 01; 45(3):381-90. PubMed ID: 17599319
    [Abstract] [Full Text] [Related]

  • 9. The metabolic puzzle during the evolution of HIV infection.
    Salas-Salvadó J, García-Lorda P.
    Clin Nutr; 2001 Oct 01; 20(5):379-91. PubMed ID: 11534932
    [Abstract] [Full Text] [Related]

  • 10. Short-term energy restriction reduces resting energy expenditure in patients with HIV lipodystrophy and hypermetabolism.
    Kosmiski LA, Bessesen DH, Stotz SA, Koeppe JR, Horton TJ.
    Metabolism; 2007 Feb 01; 56(2):289-95. PubMed ID: 17224345
    [Abstract] [Full Text] [Related]

  • 11. The basis and management of metabolic abnormalities associated with cardiovascular risk in human immunodeficiency virus infection and its treatment.
    Crook M.
    Ann Clin Biochem; 2007 May 01; 44(Pt 3):219-31. PubMed ID: 17456292
    [Abstract] [Full Text] [Related]

  • 12. Nutrition and HIV infection: review of weight loss and wasting in the era of highly active antiretroviral therapy from the nutrition for healthy living cohort.
    Mangili A, Murman DH, Zampini AM, Wanke CA.
    Clin Infect Dis; 2006 Mar 15; 42(6):836-42. PubMed ID: 16477562
    [Abstract] [Full Text] [Related]

  • 13. [Recommendations from the GESIDA/Spanish AIDS Plan regarding antiretroviral treatment in adults with human immunodeficiency virus infection (update February 2009)].
    Panel de expertos de Gesida y Plan Nacional sobre el Sida.
    Enferm Infecc Microbiol Clin; 2009 Apr 15; 27(4):222-35. PubMed ID: 19246124
    [Abstract] [Full Text] [Related]

  • 14. HIV-1 viral rebound dynamics after a single treatment interruption depends on time of initiation of highly active antiretroviral therapy.
    Steingrover R, Pogány K, Fernandez Garcia E, Jurriaans S, Brinkman K, Schuitemaker H, Miedema F, Lange JM, Prins JM.
    AIDS; 2008 Aug 20; 22(13):1583-8. PubMed ID: 18670217
    [Abstract] [Full Text] [Related]

  • 15. Audiologic and vestibular findings in a sample of human immunodeficiency virus type-1-infected Mexican children under highly active antiretroviral therapy.
    Palacios GC, Montalvo MS, Fraire MI, Leon E, Alvarez MT, Solorzano F.
    Int J Pediatr Otorhinolaryngol; 2008 Nov 20; 72(11):1671-81. PubMed ID: 18814921
    [Abstract] [Full Text] [Related]

  • 16. Weight loss and wasting in patients infected with human immunodeficiency virus.
    Grinspoon S, Mulligan K, Department of Health and Human Services Working Group on the Prevention and Treatment of Wasting and Weight Loss.
    Clin Infect Dis; 2003 Apr 01; 36(Suppl 2):S69-78. PubMed ID: 12652374
    [Abstract] [Full Text] [Related]

  • 17. Therapy insight: Body-shape changes and metabolic complications associated with HIV and highly active antiretroviral therapy.
    Falutz J.
    Nat Clin Pract Endocrinol Metab; 2007 Sep 01; 3(9):651-61. PubMed ID: 17710086
    [Abstract] [Full Text] [Related]

  • 18. The influence of HIV infection and antiretroviral therapy on the mitochondrial membrane potential of peripheral mononuclear cells.
    Sternfeld T, Schmid M, Tischleder A, Mudra S, Schlamp A, Kost BP, Gruber R, Youle M, Bogner JR, Goebel FD.
    Antivir Ther; 2007 Sep 01; 12(5):769-78. PubMed ID: 17713160
    [Abstract] [Full Text] [Related]

  • 19. Role of recombinant human growth hormone in HIV-associated wasting and cachexia: pathophysiology and rationale for treatment.
    Gelato M, McNurlan M, Freedland E.
    Clin Ther; 2007 Nov 01; 29(11):2269-88. PubMed ID: 18158071
    [Abstract] [Full Text] [Related]

  • 20. Mitochondrial DNA haplogroups and highly active antiretroviral therapy-related lipodystrophy.
    Nasi M, Guaraldi G, Orlando G, Durante C, Pinti M, Nemes E, Nardini G, Passarino G, Cocchi M, Esposito R, Mussini C, Cossarizza A.
    Clin Infect Dis; 2008 Oct 01; 47(7):962-8. PubMed ID: 18752438
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.